Chun Wang

Chun Wang is an Associate Professor in the Department of Biomedical Engineering at the University of Minnesota with significant contributions to cancer immunology and drug delivery research. They maintain affiliations with the Cancer Immunology Center and the Center for Immunology, focusing on translational research that bridges engineering principles with therapeutic applications.

Dr. Wang's research interests encompass multiple cutting-edge areas at the intersection of biomedical engineering and immunology:

• Development of innovative polymer-based drug delivery systems for controlled release applications
• Design of nanoparticle platforms specifically engineered for cancer immunotherapy
• Creative approaches to vaccine development targeting melanoma and other cancers
• Advanced hydrogel technologies with applications in embolization and therapeutic delivery
• Integration of photothermal therapy with immunological approaches for enhanced treatment efficacy

Analysis of Dr. Wang's publication record reveals a strong trajectory in translational research, with recent work demonstrating significant advances in polymer-protein nanovaccines, PEI-based nanoparticles for tumor immunotherapy, and novel hydrogel systems. Their research consistently bridges fundamental material science with clinical applications in cancer treatment, showing particular strength in applying engineering principles to solve immunological challenges.

Dr. Wang has secured substantial external funding for their research, serving as Principal Investigator on multiple significant projects:

• A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform (2023-2025, NIH and Trekka Therapeutics)
• Analysis of POE IV and Formulation of Granisetron (2021-2023, Evonik Corporation)
• Translational Development of a Melanoma Neoantigen Peptide Vaccine (2019-2020, Mayo Clinic Rochester)
• Selective and Efficacious Treatment of Cancer through Combination Approaches (2018-2019, Boston Scientific Corporation)

With 108 documented research outputs spanning from 1994 to 2025, Dr. Wang maintains an active laboratory focused on translating polymer science into clinical cancer applications, working closely with industry partners and clinical collaborators to advance novel therapeutic approaches from bench to bedside.